Crescent forms PD-1xVEGF, ADC pact with Kelun, raises $185Mnews2025-12-04T14:04:35+00:00December 4th, 2025|Endpoints News|
ARCH, Parker Institute build next big oncology bet with suite of programs and startup acquisitionnews2025-12-02T16:34:33+00:00December 2nd, 2025|Endpoints News|
Gene writing startup Tessera strikes $150M partnership with Regeneronnews2025-12-01T12:00:18+00:00December 1st, 2025|Endpoints News|
Lundbeck backs out of bidding war for sleep disorder biotech Avadelnews2025-11-26T18:11:34+00:00November 26th, 2025|Endpoints News|
Novartis was the sole bidder in $12B deal to buy Aviditynews2025-11-25T09:00:28+00:00November 25th, 2025|Endpoints News|
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeuticsnews2025-11-24T12:30:38+00:00November 24th, 2025|Endpoints News|
Flagship and portfolio companies do deals with GSK, Merck KGaA and Saudi Arabianews2025-11-20T14:27:08+00:00November 20th, 2025|Endpoints News|
Pfizer CFO says drugmaker will ‘supplement’ Metsera deal as part of broader obesity ambitionsnews2025-11-19T19:27:38+00:00November 19th, 2025|Endpoints News|
GSK picks LTZ Therapeutics in myeloid cell engager pact worth $50M upfrontnews2025-11-19T11:58:05+00:00November 19th, 2025|Endpoints News|
Alkermes ups bid for Avadel after Lundbeck tried snatching narcolepsy biotechnews2025-11-19T11:52:06+00:00November 19th, 2025|Endpoints News|
